Advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression.
VIEW PRODUCT PIPELINEAbout
We are a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders.
Read MoreNews
Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference
October 2, 2024
Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress
September 9, 2024
Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer
August 23, 2024
Xenon Reports Q2 2024 Financial Results and Business Update
August, 8, 2024
Investors
Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events
View Investor Area
